Fundraising Fox
Orionis Biosciences
Newton, US · Founded 2015 · Delaware LLC · 69 employees on LinkedIn · 6 known investors
Find your way into Orionis Biosciences
Sign up to see every warm intro you have to Orionis Biosciences
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Orionis Biosciences team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Orionis Biosciences discovers and engineers molecules that connect proteins on or within cells to reprogram disease-driving processes or activate immune responses. It develops therapeutics for cancer, autoimmune diseases, and neurodegenerative disorders through collaborations with industry and academic institutions.
Founders & leadership
Orionis Biosciences was founded in 2015 by Nikolai Kley.
Board
Investors · 6
How we know: Empire Angels's portfolio page · Not right? Tell us
How we know: Excel Venture Management's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$24.5M disclosed across 3 rounds · 2015–2018
▶$19.7MraisedApr 2018 · 9 investors · BiotechnologyRule 506(b)
- Griet Vanpoucke, Ph.D.Director
- Nikolai Kley, Ph.D.Executive Officer, Director
- Steven R. Gullans, Ph.D.Director
- Offering amount
- $25.5M
- Amount sold
- $19.7M
- First sale
- Mar 2018
- Incorporated
- Limited Liability Company, Delaware, 2015
- Federal exemptions
- 06b
▶$750KraisedJan 2017 · 1 investors · BiotechnologyRule 506(b)
- Nikolai Kley, Ph.D.Executive Officer, Director
- Griet Vanpoucke, Ph.D.Director
- Steven R. Gullans, Ph.D.Director
- Offering amount
- $5.3M
- Amount sold
- $750K
- First sale
- Jan 2017
- Incorporated
- Limited Liability Company, Delaware, 2015
- Federal exemptions
- 06b
▶$4MraisedOct 2015 · 4 investors · BiotechnologyRule 506(b)
- Griet Vanpoucke, Ph.D.Director
- Steven R. Gullans, Ph.D.Director
- Nikolai Kley, Ph.D.Executive Officer, Director
- Offering amount
- $5.3M
- Amount sold
- $4M
- First sale
- Sep 2015
- Incorporated
- Limited Liability Company, Delaware, 2015
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
3 people who came through Orionis Biosciences went on to found or lead other companies.
Related companies · 4
Companies working in the same space as Orionis Biosciences.
Frequently asked questions
- What does Orionis Biosciences do?
- Orionis Biosciences discovers and engineers molecules that connect proteins on or within cells to reprogram disease-driving processes or activate immune responses. It develops therapeutics for cancer, autoimmune diseases, and neurodegenerative disorders through collaborations with industry and academic institutions.
- Who founded Orionis Biosciences?
- Orionis Biosciences was founded by Nikolai Kley in 2015.
- Who are Orionis Biosciences's investors?
- Orionis Biosciences's investors include Empire Angels, Excel Venture Management, Solari Capital, Solasta Ventures, V-Bio Ventures, Wessel Management.
- How much funding has Orionis Biosciences raised?
- Orionis Biosciences has disclosed $24.5M raised across 3 rounds.
- Where is Orionis Biosciences headquartered?
- Orionis Biosciences is headquartered in Newton, US.